Shopping Cart 0
Cart Subtotal
USD 0

Valneva SE (VLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Valneva SE (Valneva) is a biotech company that develops lifesaving vaccines. The company's products include IXIARO, a vaccine indicated for the prevention of Japanese encephalitis; and Dukoral, a vaccine indicated for the prevention of cholera and diarrhea; clostridium difficile, lyme, chikungunya, and zika diseases. It provides EB66 cell line, a proprietary embryonic stem cell-based technology which is used for the production of human and veterinary viral and therapeutic vaccines; and IC31, a synthetic vaccine adjuvant. Valneva partners with pharmaceutical and biotech companies to develop products using its proprietary technologies. The company operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Lyon, France.

Valneva SE (VLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10

Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Valneva SE, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Valneva to Secure USD18 Million from Funds Managed by Athyrium 13

BliNK Biomedical Raises Funds through Series A Venture Financing 14

Valneva Austria Raises USD 30 Million In Venture Financing 15

Private Equity 16

Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16

Partnerships 17

InFlectis BioScience Enters into Licensing Agreement with Valneva 17

Seqirus Enters into Distribution Agreement with Valneva 18

Valneva Enters into R&D Agreement with GlaxoSmithKline 19

Valneva Enters into Distribution Agreement with PaxVax 20

PaxVax Enters into Distribution Agreement with Valneva 21

Valneva Forms Joint Venture with BliNK Therapeutics 22

Licensing Agreements 23

Emergent BioSolutions Enters into Licensing Agreement with Valneva 23

Bavarian Nordic Enters into Licensing Agreement with Valneva 24

Valneva Enters into Licensing Agreement with Jianshun Biosciences 25

Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26

Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28

Valneva to Enter into Licensing Agreement with Pharma Company 29

Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30

GeoVax Labs Enters into Licensing Agreement with Valneva 31

Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32

Equity Offering 33

Valneva Raises USD54 Million in Rights Offering 33

Valneva Completes Rights Offering Of Shares For USD 53.5 Million 35

Asset Transactions 37

Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37

Acquisition 38

Valneva Acquires Crucell Sweden for USD54 Million 38

Valneva SE-Key Competitors 39

Valneva SE-Key Employees 40

Valneva SE-Locations And Subsidiaries 41

Head Office 41

Other Locations & Subsidiaries 41

Recent Developments 43

Financial Announcements 43

Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1 43

May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs 47

Mar 22, 2018: VALNEVA Delivers Strong 2017 Financial Results and Advances Key R&D Programs 50

Nov 09, 2017: Valneva Reports Strong Operational Performance for the First Nine Months of 2017 54

Aug 31, 2017: Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress 55

May 11, 2017: VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017 60

Mar 23, 2017: VALNEVA Reports Best Financial Results in the Company's History with its First Year of Positive EBITDA in 2016 63

Feb 23, 2017: VALNEVA Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017 68

Corporate Communications 71

Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members 71

Aug 01, 2017: VALNEVA Announces Expansion of its Management Board-Strengthening Senior Management for Future Growth 72

Product News 73

Apr 10, 2017: Valneva to Present at the 17th World Vaccine Congress in Washington D.C. 73

Clinical Trials 74

Mar 29, 2018: VALNEVA to Present Data on VLA-1601 at the 18th World Vaccine Congress in Washington, D.C. 74

Feb 26, 2018: Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus 75

Other Significant Developments 76

Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan 76

Dec 11, 2017: Intercell USA Changes Name to Valneva USA and Expands Commercial Presence 77

Jun 30, 2017: Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members 78

Appendix 79

Methodology 79

About GlobalData 79

Contact Us 79

Disclaimer 79


List Of Figure

List of Figures

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Valneva SE, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Valneva SE, Deals By Therapy Area, 2012 to YTD 2018 9

Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10

Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Valneva to Secure USD18 Million from Funds Managed by Athyrium 13

BliNK Biomedical Raises Funds through Series A Venture Financing 14

Valneva Austria Raises USD 30 Million In Venture Financing 15

Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16

InFlectis BioScience Enters into Licensing Agreement with Valneva 17

Seqirus Enters into Distribution Agreement with Valneva 18

Valneva Enters into R&D Agreement with GlaxoSmithKline 19

Valneva Enters into Distribution Agreement with PaxVax 20

PaxVax Enters into Distribution Agreement with Valneva 21

Valneva Forms Joint Venture with BliNK Therapeutics 22

Emergent BioSolutions Enters into Licensing Agreement with Valneva 23

Bavarian Nordic Enters into Licensing Agreement with Valneva 24

Valneva Enters into Licensing Agreement with Jianshun Biosciences 25

Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26

Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28

Valneva to Enter into Licensing Agreement with Pharma Company 29

Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30

GeoVax Labs Enters into Licensing Agreement with Valneva 31

Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32

Valneva Raises USD54 Million in Rights Offering 33

Valneva Completes Rights Offering Of Shares For USD 53.5 Million 35

Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37

Valneva Acquires Crucell Sweden for USD54 Million 38

Valneva SE, Key Competitors 39

Valneva SE, Key Employees 40

Valneva SE, Other Locations 41

Valneva SE, Subsidiaries 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Valneva SE, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.